Atopic Dermatitis Market By Drug Class (Biologics, Calcineurin Inhibitors, PDE-4 Inhibitor, Corticosteroids, Others), By Mode Of Administration (Topical, Injectable, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global atopic dermatitis market was valued at $5,333.37 million in 2021, and is projected to reach $22,594.44 million by 2031, registering a CAGR of 15.1% from 2022 to 2031. Atopic dermatitis is a chronic, pruritic inflammatory skin condition (see image below) that typically affects the face (cheeks), neck, arms, and legs but usually spares the groin and axillary regions. Atopic dermatitis usually starts in early infancy, but also affects a substantial number of adults. Atopic dermatitis is commonly associated with elevated levels of immunoglobulin E (IgE). Atopic dermatitis is the first disease to present in a series of allergic diseases including food allergy, asthma, and allergic rhinitis, which has given rise to the atopic march theory, which suggests that atopic dermatitis is a part of a progression that may lead to subsequent allergic disease at other epithelial barrier surfaces.
The primary symptom of atopic dermatitis is dry, itchy skin that often turns into a red rash during flare-ups. Many different physical and internal factors can trigger an eczema flare-up. The resulting inflammation causes increased blood flow and the urge to itch. Eczema flares are part of the agonizing itch-scratch cycle. It’s hard to fight the physical and psychological elements that drive this cycle. Scratching feels good at the time but can lead to more inflammation and even skin infections. Atopic dermatitis has different symptoms depending on a person’s age. The atopic dermatitis market is expected to experience significant market growth during the forecast period as there has been a rapid development of novel pipeline drugs. Likewise, rise in demand for new biologics and product approvals are also predicted to enhance the atopic dermatitis market growth. Furthermore, the favorable reimbursement policies in emerging countries and high prevalence of atopic dermatitis are projected to drive the market growth rate. Moreover, increase in awareness regarding the availability of treatments for the disease and various initiatives undertaken by governments to provide better and more affordable treatment are expected to influence the atopic dermatitis market growth globally. In addition, the rapid technological advancement and the rise in funding along with increase in government support for research and development are likely to create various new opportunities for the market growth during the forecast period.
However, the easy availability of expensive treatment and poor reimbursement policies in the developing regions across the globe are expected to act as major restraints toward the growth of the atopic dermatitis market, whereas the allergic reactions of off-label therapies and patent expiry of products can challenge the growth of the target market during the forecast period. The atopic dermatitis market is segmented on the basis of drug class, route of administration, distribution channel, and region. By drug class, the market is classified into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics, and others. By indication, the market is classified into topical, injectable, and oral. By end user, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
North America accounted for the largest market share in the atopic dermatitis market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in prevalence of atopic dermatitis, high treatment awareness among the patient population across the U.S., well-established healthcare infrastructure, and early adoption of novel medications. For instance, as per the 2022 National Eczema Association, an estimated 16.5 million U.S. adults (7.3%) have atopic dermatitis that initially began at more than two years of age, with nearly 40% affected by moderate or severe disease.
The report provides a comprehensive analysis of the key players that operate in the global atopic dermatitis market. The key companies profiled in the report include AbbVie Inc., Arcutis Biotherapeutics, Inc., Asana Biosciences, Inc., Astellas Pharma, Inc., Bayer AG, Inc., Bristol-Myers Squibb Inc., Dermavant Sciences, Inc., Eli Lilly and Company, Inc., Galderma, Inc., Incyte Corporation, Inc., Leo Pharma, Inc., Novartis AG, Otsuka Pharmaceuticals Co., Ltd., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Inc., and Viatris, Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the atopic dermatitis market analysis from 2021 to 2031 to identify the prevailing atopic dermatitis market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the atopic dermatitis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global atopic dermatitis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
PDE-4 Inhibitor
Corticosteroids
Others
Biologics
Calcineurin Inhibitors
Type
Tacrolimus
Pimecrolimus
By Mode Of Administration
Topical
Injectable
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Sanofi SA
Novartis International AG
Bristol-Myers Squibb
Bayer AG
AbbVie Inc.
Pfizer Inc.
Astellas Pharma Inc.
Regeneron Pharmaceuticals Inc.
Arcutis Biotherapeutics
Asana Biosciences
Dermavant
Eli Lilly
Galderma
Incyte
Viatris
Leo Pharma
Otsuka Holdings Co.,Ltd
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: ATOPIC DERMATITIS MARKET, BY DRUG CLASS
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Biologics
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Calcineurin Inhibitors
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Calcineurin Inhibitors Atopic Dermatitis Market by Type
- 4.3.4.1 Tacrolimus Market size and forecast, by region
- 4.3.4.2 Pimecrolimus Market size and forecast, by region
- 4.4 PDE-4 Inhibitor
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Corticosteroids
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Others
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- CHAPTER 5: ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Topical
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Injectable
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Oral
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Online Pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: ATOPIC DERMATITIS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Class
- 7.2.2.1 North America Calcineurin Inhibitors Atopic Dermatitis Market by Type
- 7.2.3 North America Market size and forecast, by Mode Of Administration
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Drug Class
- 7.2.5.1.2 Market size and forecast, by Mode Of Administration
- 7.2.5.1.3 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Drug Class
- 7.2.5.2.2 Market size and forecast, by Mode Of Administration
- 7.2.5.2.3 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Drug Class
- 7.2.5.3.2 Market size and forecast, by Mode Of Administration
- 7.2.5.3.3 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Class
- 7.3.2.1 Europe Calcineurin Inhibitors Atopic Dermatitis Market by Type
- 7.3.3 Europe Market size and forecast, by Mode Of Administration
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Drug Class
- 7.3.5.1.2 Market size and forecast, by Mode Of Administration
- 7.3.5.1.3 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Drug Class
- 7.3.5.2.2 Market size and forecast, by Mode Of Administration
- 7.3.5.2.3 Market size and forecast, by Distribution Channel
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Drug Class
- 7.3.5.3.2 Market size and forecast, by Mode Of Administration
- 7.3.5.3.3 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Drug Class
- 7.3.5.4.2 Market size and forecast, by Mode Of Administration
- 7.3.5.4.3 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Drug Class
- 7.3.5.5.2 Market size and forecast, by Mode Of Administration
- 7.3.5.5.3 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Drug Class
- 7.3.5.6.2 Market size and forecast, by Mode Of Administration
- 7.3.5.6.3 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
- 7.4.2.1 Asia-Pacific Calcineurin Inhibitors Atopic Dermatitis Market by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Mode Of Administration
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Drug Class
- 7.4.5.1.2 Market size and forecast, by Mode Of Administration
- 7.4.5.1.3 Market size and forecast, by Distribution Channel
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Drug Class
- 7.4.5.2.2 Market size and forecast, by Mode Of Administration
- 7.4.5.2.3 Market size and forecast, by Distribution Channel
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Drug Class
- 7.4.5.3.2 Market size and forecast, by Mode Of Administration
- 7.4.5.3.3 Market size and forecast, by Distribution Channel
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Drug Class
- 7.4.5.4.2 Market size and forecast, by Mode Of Administration
- 7.4.5.4.3 Market size and forecast, by Distribution Channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Drug Class
- 7.4.5.5.2 Market size and forecast, by Mode Of Administration
- 7.4.5.5.3 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Drug Class
- 7.4.5.6.2 Market size and forecast, by Mode Of Administration
- 7.4.5.6.3 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Class
- 7.5.2.1 LAMEA Calcineurin Inhibitors Atopic Dermatitis Market by Type
- 7.5.3 LAMEA Market size and forecast, by Mode Of Administration
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Drug Class
- 7.5.5.1.2 Market size and forecast, by Mode Of Administration
- 7.5.5.1.3 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Drug Class
- 7.5.5.2.2 Market size and forecast, by Mode Of Administration
- 7.5.5.2.3 Market size and forecast, by Distribution Channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Drug Class
- 7.5.5.3.2 Market size and forecast, by Mode Of Administration
- 7.5.5.3.3 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Drug Class
- 7.5.5.4.2 Market size and forecast, by Mode Of Administration
- 7.5.5.4.3 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Sanofi SA
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Novartis International AG
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Bristol-Myers Squibb
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Bayer AG
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 AbbVie Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Pfizer Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Astellas Pharma Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Regeneron Pharmaceuticals Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Arcutis Biotherapeutics
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Asana Biosciences
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Dermavant
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Eli Lilly
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Galderma
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Incyte
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Viatris
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- 9.16 Leo Pharma
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
- 9.17 Otsuka Holdings Co.,Ltd
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 2. ATOPIC DERMATITIS MARKET, FOR BIOLOGICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. ATOPIC DERMATITIS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. ATOPIC DERMATITIS MARKET, FOR CALCINEURIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. ATOPIC DERMATITIS MARKET FOR CALCINEURIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. GLOBAL CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 7. ATOPIC DERMATITIS MARKET, FOR TACROLIMUS, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. ATOPIC DERMATITIS MARKET, FOR PIMECROLIMUS, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. ATOPIC DERMATITIS MARKET, FOR PDE-4 INHIBITOR, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. ATOPIC DERMATITIS MARKET FOR PDE-4 INHIBITOR, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 11. ATOPIC DERMATITIS MARKET, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. ATOPIC DERMATITIS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. ATOPIC DERMATITIS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. ATOPIC DERMATITIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 16. ATOPIC DERMATITIS MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. ATOPIC DERMATITIS MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 18. ATOPIC DERMATITIS MARKET, FOR INJECTABLE, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. ATOPIC DERMATITIS MARKET FOR INJECTABLE, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 20. ATOPIC DERMATITIS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. ATOPIC DERMATITIS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 22. GLOBAL ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 23. ATOPIC DERMATITIS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. ATOPIC DERMATITIS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. ATOPIC DERMATITIS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 26. ATOPIC DERMATITIS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 27. ATOPIC DERMATITIS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 28. ATOPIC DERMATITIS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 29. ATOPIC DERMATITIS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 32. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 33. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 34. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 35. U.S. ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 36. U.S. ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 37. U.S. ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 38. CANADA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 39. CANADA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 40. CANADA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 41. MEXICO ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 42. MEXICO ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 43. MEXICO ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 44. EUROPE ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 45. EUROPE CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 46. EUROPE ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 47. EUROPE ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 48. EUROPE ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 49. GERMANY ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 50. GERMANY ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 51. GERMANY ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 52. FRANCE ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 53. FRANCE ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 54. FRANCE ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 55. UK ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 56. UK ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 57. UK ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 58. ITALY ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 59. ITALY ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 60. ITALY ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 61. SPAIN ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 62. SPAIN ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 63. SPAIN ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 64. REST OF EUROPE ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 65. REST OF EUROPE ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 66. REST OF EUROPE ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 69. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 70. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 71. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 72. JAPAN ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 73. JAPAN ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 74. JAPAN ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 75. CHINA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 76. CHINA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 77. CHINA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 79. AUSTRALIA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 80. AUSTRALIA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 81. INDIA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 82. INDIA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 83. INDIA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 84. SOUTH KOREA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 85. SOUTH KOREA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 86. SOUTH KOREA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 87. REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 88. REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 89. REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 90. LAMEA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 91. LAMEA CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 92. LAMEA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 93. LAMEA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 94. LAMEA ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 95. BRAZIL ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 96. BRAZIL ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 97. BRAZIL ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 98. SAUDI ARABIA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 99. SAUDI ARABIA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 100. SAUDI ARABIA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 101. SOUTH AFRICA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 102. SOUTH AFRICA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 103. SOUTH AFRICA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 104. REST OF LAMEA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 105. REST OF LAMEA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 106. REST OF LAMEA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 107.SANOFI SA: COMPANY SNAPSHOT
- TABLE 108.SANOFI SA: OPERATING SEGMENTS
- TABLE 109.SANOFI SA: PRODUCT PORTFOLIO
- TABLE 110.SANOFI SA: NET SALES,
- TABLE 111.SANOFI SA: KEY STRATERGIES
- TABLE 112.NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
- TABLE 113.NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
- TABLE 114.NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
- TABLE 115.NOVARTIS INTERNATIONAL AG: NET SALES,
- TABLE 116.NOVARTIS INTERNATIONAL AG: KEY STRATERGIES
- TABLE 117.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
- TABLE 118.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
- TABLE 119.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
- TABLE 120.BRISTOL-MYERS SQUIBB: NET SALES,
- TABLE 121.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
- TABLE 122.BAYER AG: COMPANY SNAPSHOT
- TABLE 123.BAYER AG: OPERATING SEGMENTS
- TABLE 124.BAYER AG: PRODUCT PORTFOLIO
- TABLE 125.BAYER AG: NET SALES,
- TABLE 126.BAYER AG: KEY STRATERGIES
- TABLE 127.ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 128.ABBVIE INC.: OPERATING SEGMENTS
- TABLE 129.ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 130.ABBVIE INC.: NET SALES,
- TABLE 131.ABBVIE INC.: KEY STRATERGIES
- TABLE 132.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 133.PFIZER INC.: OPERATING SEGMENTS
- TABLE 134.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 135.PFIZER INC.: NET SALES,
- TABLE 136.PFIZER INC.: KEY STRATERGIES
- TABLE 137.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
- TABLE 138.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
- TABLE 139.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
- TABLE 140.ASTELLAS PHARMA INC.: NET SALES,
- TABLE 141.ASTELLAS PHARMA INC.: KEY STRATERGIES
- TABLE 142.REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
- TABLE 143.REGENERON PHARMACEUTICALS INC.: OPERATING SEGMENTS
- TABLE 144.REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
- TABLE 145.REGENERON PHARMACEUTICALS INC.: NET SALES,
- TABLE 146.REGENERON PHARMACEUTICALS INC.: KEY STRATERGIES
- TABLE 147.ARCUTIS BIOTHERAPEUTICS: COMPANY SNAPSHOT
- TABLE 148.ARCUTIS BIOTHERAPEUTICS: OPERATING SEGMENTS
- TABLE 149.ARCUTIS BIOTHERAPEUTICS: PRODUCT PORTFOLIO
- TABLE 150.ARCUTIS BIOTHERAPEUTICS: NET SALES,
- TABLE 151.ARCUTIS BIOTHERAPEUTICS: KEY STRATERGIES
- TABLE 152.ASANA BIOSCIENCES: COMPANY SNAPSHOT
- TABLE 153.ASANA BIOSCIENCES: OPERATING SEGMENTS
- TABLE 154.ASANA BIOSCIENCES: PRODUCT PORTFOLIO
- TABLE 155.ASANA BIOSCIENCES: NET SALES,
- TABLE 156.ASANA BIOSCIENCES: KEY STRATERGIES
- TABLE 157.DERMAVANT: COMPANY SNAPSHOT
- TABLE 158.DERMAVANT: OPERATING SEGMENTS
- TABLE 159.DERMAVANT: PRODUCT PORTFOLIO
- TABLE 160.DERMAVANT: NET SALES,
- TABLE 161.DERMAVANT: KEY STRATERGIES
- TABLE 162.ELI LILLY: COMPANY SNAPSHOT
- TABLE 163.ELI LILLY: OPERATING SEGMENTS
- TABLE 164.ELI LILLY: PRODUCT PORTFOLIO
- TABLE 165.ELI LILLY: NET SALES,
- TABLE 166.ELI LILLY: KEY STRATERGIES
- TABLE 167.GALDERMA: COMPANY SNAPSHOT
- TABLE 168.GALDERMA: OPERATING SEGMENTS
- TABLE 169.GALDERMA: PRODUCT PORTFOLIO
- TABLE 170.GALDERMA: NET SALES,
- TABLE 171.GALDERMA: KEY STRATERGIES
- TABLE 172.INCYTE: COMPANY SNAPSHOT
- TABLE 173.INCYTE: OPERATING SEGMENTS
- TABLE 174.INCYTE: PRODUCT PORTFOLIO
- TABLE 175.INCYTE: NET SALES,
- TABLE 176.INCYTE: KEY STRATERGIES
- TABLE 177.VIATRIS: COMPANY SNAPSHOT
- TABLE 178.VIATRIS: OPERATING SEGMENTS
- TABLE 179.VIATRIS: PRODUCT PORTFOLIO
- TABLE 180.VIATRIS: NET SALES,
- TABLE 181.VIATRIS: KEY STRATERGIES
- TABLE 182.LEO PHARMA: COMPANY SNAPSHOT
- TABLE 183.LEO PHARMA: OPERATING SEGMENTS
- TABLE 184.LEO PHARMA: PRODUCT PORTFOLIO
- TABLE 185.LEO PHARMA: NET SALES,
- TABLE 186.LEO PHARMA: KEY STRATERGIES
- TABLE 187.OTSUKA HOLDINGS CO.,LTD: COMPANY SNAPSHOT
- TABLE 188.OTSUKA HOLDINGS CO.,LTD: OPERATING SEGMENTS
- TABLE 189.OTSUKA HOLDINGS CO.,LTD: PRODUCT PORTFOLIO
- TABLE 190.OTSUKA HOLDINGS CO.,LTD: NET SALES,
- TABLE 191.OTSUKA HOLDINGS CO.,LTD: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.ATOPIC DERMATITIS MARKET SEGMENTATION
- FIGURE 2.ATOPIC DERMATITIS MARKET,2021-2031
- FIGURE 3.ATOPIC DERMATITIS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.ATOPIC DERMATITIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.ATOPIC DERMATITIS MARKET,BY DRUG CLASS,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF BIOLOGICS ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PDE-4 INHIBITOR ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 18.ATOPIC DERMATITIS MARKET,BY MODE OF ADMINISTRATION,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TOPICAL ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INJECTABLE ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ORAL ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 22.ATOPIC DERMATITIS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES ATOPIC DERMATITIS MARKET,2021-2031(%)
- FIGURE 26.ATOPIC DERMATITIS MARKET BY REGION,2021
- FIGURE 27.U.S. ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 28.CANADA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 29.MEXICO ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 30.GERMANY ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 31.FRANCE ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 32.UK ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 33.ITALY ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 34.SPAIN ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 35.REST OF EUROPE ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 36.JAPAN ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 37.CHINA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 38.AUSTRALIA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 39.INDIA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 40.SOUTH KOREA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 41.REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 42.BRAZIL ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 43.SAUDI ARABIA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 44.SOUTH AFRICA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 45.REST OF LAMEA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
- FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 50.COMPETITIVE DASHBOARD
- FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 52.SANOFI SA.: NET SALES ,($MILLION)
- FIGURE 53.NOVARTIS INTERNATIONAL AG.: NET SALES ,($MILLION)
- FIGURE 54.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)
- FIGURE 55.BAYER AG.: NET SALES ,($MILLION)
- FIGURE 56.ABBVIE INC..: NET SALES ,($MILLION)
- FIGURE 57.PFIZER INC..: NET SALES ,($MILLION)
- FIGURE 58.ASTELLAS PHARMA INC..: NET SALES ,($MILLION)
- FIGURE 59.REGENERON PHARMACEUTICALS INC..: NET SALES ,($MILLION)
- FIGURE 60.ARCUTIS BIOTHERAPEUTICS.: NET SALES ,($MILLION)
- FIGURE 61.ASANA BIOSCIENCES.: NET SALES ,($MILLION)
- FIGURE 62.DERMAVANT.: NET SALES ,($MILLION)
- FIGURE 63.ELI LILLY.: NET SALES ,($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook